Assay Development, Licensing and Treatment

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Assay Development

Licensing

Treatment

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

The Pharma Data

JANUARY 27, 2021

BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with Eurofins Discovery for TD-0148A’s U.S. VANCOUVER, Jan.

FDA

FDA Synthetic Chemistry Assay Development Treatment

The hidden risks of over-reliance on healthy donor material

Drug Target Review

OCTOBER 10, 2024

Diseased cells can respond differently to treatment, leading to unforeseen adverse events, including severe toxicity and even death. Addressing unexpected manufacturing challenges, safety concerns, or efficacy issues in later stages can significantly delay clinical development and escalate costs.

Therapies

Therapies Immune Response Clinical Trials Disease

Drug Discovery Digest

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

The hidden risks of over-reliance on healthy donor material

Stay Connected